A peer-level look at how laboratory managers, supervisors, and directors weigh automation value against validation burden, specimen risk, quality-control oversight, capital requirements, and the emerging role of AI-assisted interpretation.
Audience: Lab Managers / Supervisors / Directors
Countries: 3
Completion Rate: 66.7%
SGID: 9014763
-Hero findings
– Quick Read — Key Findings
For laboratory managers, supervisors, and directors, the practical question is not whether repetitive work can be automated. It is which workflow to automate first, how to validate it, what exceptions must remain visible, and whether the operating model can justify the capital required to scale.
That tension runs through this MDForLives survey. Respondents point to no single dominant entry point: opportunity is spread across accessioning, sample preparation and analytical testing, while value is broad, with total laboratory automation leading the capability ranking and faster turnaround and throughput leading the investment case.
Quality governance remains the counterweight. ISO 15189:2022 frames laboratory performance around quality and competence, and U.S. CLIA requires quality systems for specimen identification and integrity, test systems, quality control and corrective actions. Automation can change who performs a step, but not the laboratory’s responsibility for reliable results.
The survey produces an exact three-way split across the major laboratory workflow stages.
Specimen accessioning, sample preparation and analytical testing are each selected by 33.3%, with no single stage dominating the automation agenda. That is an operational signal: roadmaps may need to start with process mapping rather than technology selection, since a lab constrained by receiving and routing has a different problem from one limited by preparation or analytical capacity, and automation is not a standard package that creates the same value everywhere.
38.4% select teeth whitening and 34.9% porcelain veneers as the cosmetic request most often following social-media exposure.
Half of respondents select total laboratory automation as the capability with the greatest operational value.
Total laboratory automation leads the capability ranking at 50.0%, ahead of robotic specimen handling (25.0%), automated result verification (16.7%) and middleware orchestration (8.3%). The most valued option is the broadest one, so managers see the largest payoff when automation connects steps rather than mechanizing one task, though connected automation also creates more interfaces, rules and dependencies to validate and monitor.
Complex specimen characteristics lead the validation question, while specimen identification and automated result verification tie as the top quality risks.
On what most warrants additional validation, 41.7% select complex specimen characteristics and 33.3% new instrument-LIS integration; on quality risk, specimen identification errors and automated result verification are each selected by 41.7%. The concerns cluster where specimens are atypical and where automated decisions replace a manual check.
Respondents do not appear to want human review everywhere. They want it where an automated pathway encounters uncertainty or risk.
Quality-control review is the strongest human-oversight priority at 41.7%, with complex result interpretation and critical result verification each at 25.0%. The mandatory-intervention question echoes it: specimen integrity concerns and critical result discrepancies are each selected by 33.3%, so human review is being concentrated on exceptions, QC and clinically significant results.
The survey separates the reason to invest from the reason investment may stall.
Reduced turnaround and higher throughput each justify continued investment for 50.0%, with lower manual workload (33.3%) and lower analytical error rates (25.0%) behind, yet 75.0% say capital expenditure most limits scale-up, ahead of workforce reskilling (16.7%) and downtime (8.3%). The operational value is not weak, but the threshold for expanding automation remains financially demanding.
Looking ahead, 45.5% expect AI-assisted result interpretation to transform laboratories within 3 to 5 years, ahead of intelligent orchestration (27.3%), autonomous robotics (18.2%) and predictive maintenance (9.1%), so the next phase may add decision support, not only physical robotics.
The survey suggests lab managers see automation as a way to improve flow, throughput and turnaround, but not as a reason to remove professional judgment from quality-sensitive work. Specimen integrity, critical discrepancies, QC review and complex interpretation remain areas where human attention is deliberately preserved.
That balance matters more as laboratories move from mechanical automation toward AI-assisted interpretation and intelligent orchestration: the more a system can decide or route on its own, the more clearly labs must define validation, escalation, accountability and monitoring. The unresolved issue is not whether automation can do more, but whether labs can scale it without losing visibility into the points where quality can fail.
You have read the summary
Dive deeper into the research, or take part in future studies that turn real healthcare perspectives into meaningful insights.
Direct answers to common questions about automation, validation, quality oversight, LIS integration, and AI in clinical laboratories.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
